Adherence to oral endocrine therapy for breast cancer: A nursing perspective

Clinical Journal of Oncology Nursing

Volumn 12, Issue 2, 2008, Pages 213-221

  Miaskowski, Christine ^a   Shockney, Lillie ^b   Chlebowski, Rowan T ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL COMPETENCE; FEMALE; HUMAN; INTERPERSONAL COMMUNICATION; METHODOLOGY; MOTIVATION; NURSE ATTITUDE; NURSE PATIENT RELATIONSHIP; NURSING; ONCOLOGY NURSING; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; STATISTICS;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL COMPETENCE; COMMUNICATION; FEMALE; HUMANS; MOTIVATION; NURSE'S ROLE; NURSE-PATIENT RELATIONS; ONCOLOGIC NURSING; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; RISK FACTORS;

EID: 45549095232     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.213-221     Document Type: Article

References (56)

1. Barber, N. (2002). Should we consider non-compliance a medical error? Quality and Safety in Health Care, 11 (1), 81-84.
2. Baum, M., Buzdar, A., Cuzick, J., Forbes, J., Houghton, J., Howell, A., et al. (2003). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmeno-pausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial effcacy and safety update analyses. Cancer, 98(9), 1802-1810.
3. Bergman-Evans, B. (2006). AIDES to improving medication adherence in older adults. Geriatric Nursing, 27(3), 174-182.
4. Boman, L., Andersson, J.U., & Bjorvell, H. (1997). Needs as expressed by women after breast cancer surgery in the setting of a short hospital stay. Scandinavian Journal of Caring Sciences, 11 (1), 25-32.
5. Bond, W.S., & Hussar, D.A. (1991). Detection methods and strategies for improving medication compliance. American Journal of Hospital Pharmacy, 48(9), 1978-1988.
6. Brown, C., Battista, D.R., Bruehlman, R., Sereika, S.S., Thase, M.E., & Dunbar-Jacob, J. (2005). Beliefs about antidepressant medications in primary care patients: Relationship to self-reported adherence. Medical Care, 43(12), 1203-1207.
7. Burgess, C., Cornelius, V., Love, S., Graham, J., Richards, M., & Ramirez, A. (2005). Depression and anxiety in women with early breast cancer: Five year observational cohort study. BMJ, 330(7493), 702-705.
8. Chlebowski, R.T., & Geller, M.L. (2007). Adherence to endocrine therapy for breast cancer. Oncology, 71(1-2), 1-9.
9. Classen, C., Butler, L.D., Koopman, C., Miller, E., DiMiceli, S., Giese-Davis, J., et al. (2001). Supportive-expressive group therapy and distress in patients with metastatic breast cancer: A randomized clinical intervention trial. Archives in General Psychiatry, 58 (5), 494-501.
10. Clowes, J.A., Peel, N.F.A., & Eastell, R. (2004). The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. Journal of Clinical Endocrinolog y and Metabolism, 89(3), 1117-1123.
11. Coombes, R.C., Hall, E., Gibson, L.J., Paridaens, R., Jassem, J., De-lozier, T., et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350(11), 1081-1092.
12. Cramer, J.A. (2002). Effect of partial compliance on cardiovascular medication effectiveness. Heart, 88(2), 203-206.
13. Davidson, B., Vogel, V., & Wickerham, L. (2006). How conversations about adjuvant hormonal therapy differ from 'typical' oncology discussions: Results of an observational linguistic study [Abstract]. Proceedings of the 2006 American Society of Clinical Oncology annual meeting. Journal of Clinical Oncology, 24(18, Suppl.), 6141.
14. De Geest, S., von Renteln-Kruse, W., Steeman, E., Degraeve, S., & Abraham, I.L. (1998). Compliance issues with the geriatric population: Complexity with aging. Nursing Clinics of North America, 33(3), 467-480.
15. Demissie, S., Silliman, R.A., & Lash, T.L. (2001). Adjuvant tamox-ifen: Predictors of use, side effects, and discontinuation in older women. Journal of Clinical Oncology, 19 (2), 322-328.
16. DeNatale, M.L. (2007). Understanding the Medicare Par t D prescription program: Partnerships for benefciaries and health care professionals. Policy, Politics, and Nursing Practice, 8(3), 170-181.
17. Dunbar-Jacob, J., Erlen, J.A., Schlenk, E.A., Ryan, C.M., Sereika, S.M., & Doswell, W.M. (2000). Adherence in chronic disease. Annual Review of Nursing Research, 18, 48-90.
18. Early Breast Cancer Trialists' Collaborative Group. (1998). Tamoxifen for early breast cancer: A n over view of the randomised trials. Lancet, 351 (9114), 1451-1467.
19. Fallowfeld, L. (2005). Acceptance of adjuvant therapy and quality of life issues. Breast, 14 (6), 612-616.
20. Fink, A.K., Gurwitz, J., Rakowski, W., Guadagnoli, E., & Silliman, R.A. (2004). Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. Journal of Clinical Oncology, 22(16), 3309-3315.
21. Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kava-nah, M., Cronin, W.M., et al. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 90(18), 1371-1388.
22. Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D.L., Wolmark, N., et al. (1996). Five versus more than fve years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute, 88(21), 1529 -154 2.
23. Gi lbert, J.R., Evans, C.E., Haynes, R.B., & Tug well, P. (1980). Predicting compliance with a regimen of digoxin therapy in family practice. Canadian Medical Association Journal, 123(2), 119-122.
24. Goss, P.E., Ingle, J.N., Martino, S., Robert, N.J., Muss, H.B., Piccart, M.J., et al. (2005). Randomized trial of letrozole following tamox-ifen as extended adjuvant therapy in receptor-positive breast cancer: Updated fndings from NCIC CTG MA.17. Journal of the National Cancer Institute, 97(172), 1262-1271.
25. Green, B.L., Rowland, J.H., Krupnick, J.L., Epstein, S.A., Stockton, P., Stern, N.M., et al. (1998). Prevalence of posttraumatic stress disorder in women with breast cancer. Psychosomatics, 39(2), 102 -111.
26. Grunfeld, E.A., Hunter, M.S., Sikka, P., & Mittal, S. (2005). Adherence beliefs among breast cancer patients taking tamoxifen. Patient Education and Counseling, 59(1), 97-102.
27. Hartigan, K. (2003). Patient education: The cornerstone of successful oral chemotherapy treatment. Clinical Journal of Oncology Nursing, 7(6, Suppl.), 21-24.
28. Haynes, R.B., McDonald, H.P., & Garg, A.X. (2002). Helping patients follow prescribed treatment: Clinical applications. JAMA, 288(22), 2880-2883.
29. Haynes, R.B., Yao, X., Degani, A., Kripalani, S., Garg, A., McDonald, H.P. (2005). Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews, CD000011.
30. Hill, J. (2005). Adherence with drug therapy in the rheumatic diseases. Part one: A review of adherence rates. Musculoskeletal Care, 3(2), 61-73.
31. Howell, A., Cuzick, J., Baum, M., Buzdar, A., Dowsett, M., Forbes, J.F., et al. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365(9453), 60-62.
32. Jenkins, V., Fallowfeld, L.J., & Poole, K. (2001). Are members of multidisciplinary teams in breast cancer aware of each other's informational roles? Quality in Health Care, 10 (2), 70-75.
33. Jenkins, V., Shilling, V., Deutsch, G., Bloomfeld, D., Morris, R., Allan, S., et al. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94(6), 828-834.
34. Jenkins, V., Shilling, V., Fallowfeld, L., Howell, A., & Hutton, S. (2004). Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology, 13 (1), 61-66.
35. Kirk, M., & Hudis, C. (2006, June). Adherence to prescribed oral medications: Understanding the barriers to optimizing hormonal therapy in breast cancer (BC). Poster session presented at the American Society of Clinical Oncology 42nd Annual Meeting, Atlanta, GA.
36. Lash, T.L., Fox, M.P., Westrup, J.L., Fink, A.K., & Silliman, R.A. (2006). Adherence to tamoxifen over the fve-year course. Breast Cancer Research and Treatment, 99(2), 215-220.
37. Lev, E.L. (1997). Bandura's theory of self-efficacy: Applications to oncology. Scholarly Inquiry for Nursing Practice, 11 (1), 21-37.
38. Liu, J.E., Mok, E., & Wong, T. (2006). Caring in nursing: Investigating the meaning of caring from the perspective of cancer patients in Beijing, China. Journal of Clinical Nursing, 15 (2), 188-196.
39. Long-Term Intervention With Pravastatin in Ischaemic Disease Study Group. (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339(19), 1349-1357.
40. Martin, B., Barghout, V., & Hutchins, L. (2006). Compliance and persistence of tamoxifen and aromatase inhibitors in breast cancer patients [Abstract 179]. European Journal of Cancer, 42(4), 96.
41. Maurice, A., Howell, A., Evans, D.G., O'Neil, A.C., & Scobie, S. (2006). Predicting compliance in a breast cancer prevention trial. Breast Journal, 12(5), 446-450.
42. Morisky, D.E., Green, L.W., & Levine, D.M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 24(1), 67-74.
43. Murthy, V., Bharia, G., & Sarin, R. (2002). Tamoxifen non-compliance: Does it matter? [Letter to the editor]. Lancet Oncology, 3(11), 654.
44. Owusu, C., Buist, D., Field, T., Lash, T.L., Thwin, S., & Silliman, R. (2006). Tamoxifen discontinuance among women aged 65 years and older with estrogen receptor positive breast cancer [Abstract]. Proceedings of the 2006 ASCO annual meeting. Journal of Clinical Oncology, 24(18, Suppl.), 648.
45. Palmer, S.C., Kagee, A., Coyne, J.C., & DeMichele, A. (2004). Experience of trauma, distress, and posttraumatic stress disorder among breast cancer patients. Psychosomatic Medicine, 66(2), 258-264.
46. Partridge, A.H., LaFountain, A., Taylor, B.S., & Asnis-Alibozek, A. (2006, December). Adherence with adjuvant anastrozole therapy among women with early-stage breast cancer. Poster session presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
47. Partridge, A.H., Wang, P.S., Winer, E.P., & Avorn, J. (2003). Nonad-herence to adjuvant tamoxifen therapy in women with primary breast cancer. Journal of Clinical Oncology, 21 (4), 602-606.
48. Powles, T., Eeles, R., Ashley, S., Easton, D., Chang, J., Dowsett, M., et al. (1998). Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemopreven-tion trial. Lancet, 352 (9122), 98-101.
49. Smith, D.L. (1989). Compliance packaging: A patient education tool. American Pharmacy, NS29(2), 42-53.
50. Stephenson, B.J., Rowe, B.H., Haynes, R.B., Macharia, W.M., & Leon, G. (1993). The rational clinical examination: Is this patient taking the treatment as prescribed? JAMA, 269(21), 2779-2781.
51. Stilley, C.S., Sereika, S., Muldoon, M.F., Ryan, C.M., & Dunbar-Jacob, J. (2004). Psychological and cognitive function: Predictors of adherence with cholesterol lowering treatment. Annals of Behavioral Medicine, 27(2), 117-124.
52. Turner, P., & Williams, C. (2002). Informed consent: Patients listen and read, but what information do they retain? New Zealand Medical Journal, 115(1164), U218.
53. United Kingdom Prospective Diabetes Study Group. (1995). 13: Relative effcacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ, 310 (6972), 83-88.
54. Waterhouse, D.M., Calzone, K.A., Mele, C., & Brenner, D.E. (1993). Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology, 11 (6), 1189-1197.
55. Wroth, T.H., & Pathman, D.E. (2006). Primary medication adherence in a rural population: The role of the patient-physician relationship and satisfaction with care. Journal of the American Board of Family Medicine, 19 (5), 478-486.
56. Yen, T.W., Hunt, K.K., Mirza, N.Q., Thomas, E.S., Singletary, S.E., Babiera, G.V., et al. (2004). Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer, 100 (5), 942-949.